NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents

Table 1 Clinical characteristics of TCGA HPV(−) cohort by NSD1 mutation status

	Mutated NSD1, n = 60		Wild-type NSD1, n = 397		p-value*
	n	%	n	%
Avg. age at diagnosis (years)	60.0		61.6		0.25
Sex					0.16
Female	13	21.7	121	30.5
Male	47	78.3	276	69.5
Race					0.59
American Indian or Alaska Native	0	0.0	2	0.5
Asian	0	0.0	11	2.8
Black or African American	7	11.7	38	9.6
White	50	83.3	334	84.1
Unknown	3	5.0	12	3.0
Smoking History					< 0.001
Never Smoker	2	3.3	99	24.9
Current Smoker	32	53.3	129	32.5
Former Smoker	25	41.7	158	39.8
Blank	1	1.7	11	2.8
Alcohol Use					0.37
No	15	25.0	134	33.8
Yes	44	73.3	254	64.0
Unknown	1	1.7	9	2.3
Stage^a					0.15
Stage I, II	9	15.0	97	24.4
Stage III	19	31.7	81	20.4
Stage IV	31	51.7	207	52.1
Unknown	1	1.7	12	3.0

*p-value is calculated from chi-square test for categorical variables or Wilcoxon rank-sum test for age (continuous)
^aStages assigned using AJCC 7th edition (76%), 6th edition (21%), 5th edition (2%), and 4th edition (< 1%)

ISSN: 2059-7347